Cite
HARVARD Citation
McCrimmon, R. et al. (2021). Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial. Diabetes, obesity & metabolism. 23 (6), pp. 1221-1231. [Online].